Fusidic acid for Behçet's colitis: a novel approach to T-cell specific immunosuppressive therapy

Dan Med Bull. 1991 Jun;38(3):284.

Abstract

A 33-year-old patient suffered from recurring Beh,cet's colitis despite treatment with corticosteroids and later cyclosporin. The patient was then successfully shifted from cyclosporin, a T-cell specific immunosuppressant, to fusidic acid treatment (500 mg t.i.d.). During fusidic acid treatment, he went into complete remission, and his prednisolone dose could be reduced from 30 to 5 mg/day. The case report substantiates recent in vitro data indicating that fusidic acid has a similar effect on T-cell function as cyclosporin. It is suggested that the effect of fusidic acid in other chronic immunoinflammatory diseases should be examined.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Behcet Syndrome / complications
  • Behcet Syndrome / drug therapy*
  • Behcet Syndrome / immunology
  • Colitis / complications
  • Colitis / drug therapy
  • Colitis / immunology
  • Fusidic Acid / therapeutic use*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology

Substances

  • Immunosuppressive Agents
  • Fusidic Acid